Teladoc Investor Day Presentation Deck

Summary Broad-based, highly visible revenue growth Increasingly efficient operating expense fuels top-line growth and margin expansion Internally generated free cash flow to fund investments in future growth & operational excellence Access to capital markets allows us to continue our successful track record of disciplined M&A that increases our market share, scale, and relevance Long-term revenue guidance of 20% – 30% annual organic growth with 200 to 300 bps of Adj. EBITDA margin expansion per year Teladoc HEALTH Teladoc Health, Inc Investor Day 2020 137

View entire presentation